Saumi Totolo
Proficient in GLP‑1 peptide structural modification and lipidation chemical transformation, scalable manufacturing via SPPS‑LPPS combined synthesis technology, product certification analysis relying on HPLC and MS for Certificate of Authentication validation, alongside the development and process optimization of GMP-compliant 3D printed sustained-release delivery systems for peptide pharmaceuticals.
Na kena vakarautaki na GLP‐1 Peptide veisautaki kei na kena vakalevutaki na cakacaka me baleta na parokaramu ni vakadewa

Railesuva na Veiliutaki: Na bolebole ni vakadewa ena idinia ni Incretin .
Na peptide vaka na suka-1. (GLP-1) veivakabulabulataki ni veivakabulabulataki kei na veivakabulabulataki ni incretin rua/tolu (GLP-1/GIP/Sukakoni) matataka e dua na kalasi ni veiqaravi vakavuniwai veisautaki duadua ena mate ni metabolic ., levulevu, kei na leqa ni mona .. Ia, vakadewataka e dua na ivakarau ni GLP-1 ni manumanu kila ki na dua na wainimate gaga vakabisinisi e vakaraitaka na veivakataotaki bibi ni kemikali kei na biophysical. GLP-1 ni vanua dina. (7-36) amide vakaraitaka e dua na bula tiko veimama ni bula ni plasma ($t_{1/2}$) ni lailai mai na . 2 miniti ena vuku ni proteolysis totolo mai na Dipeptidyl Peptidase-4. (DPP-IV) at the $\text{Ala}^8-\text{Glu}^ 9$ veiwekani ni peptide, cokovata kei na vakasavasavataki ni renal ($NMWCO \approx 30-50\text{ kDa}$).
Me rawati vakadua ena veimacawa se vakadua ena veivula na veiqaravi vakavuniwai ., na parokaramu ni vakadewa e dodonu me vakacurumi kina na veisau vereverea ni kemikali —okati kina na amino acid sega ni vakayago e vakataotaki vakalevu ., asila ni uro ena yasa ni sinucodo (vakawaicalataki), Poly vakatabakidua ni vanua(etileni kalaikoli) (PEGila), kei na liga ni ivakatakilakila ni veisele. Se bera, digidigi taumada e caka ena gauna ni kunei-ivakatagedegede ni peptide ni iwasewase kaukauwa (SPSS) dau bulia na ivakarau ni leqa bibi ena gauna ni vakalevutaki-cake:
- Vakasoqoni vata & Gela: Hydrophobic fatty acid side chains or polydisperse PEG polymers drive intermolecular $\beta$-sheet self-assembly during cleavage and purification.
- Na veika dukadukali: E vuqa na ikalawa ni iwali-wasewase ni veimaliwai ni lipophilic vereverea e vakalevutaka na veivakaduiduitaki ena veivanua ni chiral.
- Maskara ni vakadidike: Co-vakacacani ni peptides ni bokoci voleka ($n-1., n-2$) kei na veimataqali vakacacani ni yasa ni isobaric ($D\text{-Asp}$, $\beta\text{-Asp}$) ena gauna ni veisautaki ni iwasewase cecere ni cakacaka ni wai (RP-HPLC).
- Na iwalewale ni sega ni laini: Na vakalevutaki mai na levu ni vakadidike ni milikaramu ki na buli ni pailate ni milikaramu kei na kilokaramu e kauta mai na vakavodoki ni levu ni chromatographic sega ni laini kei na vakacacani ni katakata.
Na ituvatuva oqo e vakamacalataka e dua na iwalewale ni idinia ni itinitini-ki-itinitini ka semati kina na digidigi ni veisautaki ni veitarataravi ni itekitekivu vakadodonu ki na downstream scale-cake ., vakadeitaki ni vakadidike, tubu cake tiko na digidigi ni buli iyaya me vaka na GMP-vakarau 3D tabaki, kei na kena muri na lawa ni ICH.
Ivakatagedegede 1 — Veisau ni Veitaratara Taumada . & Kemisitiri ni veimama ni bula
Na kena tuvai e dua na vakadewa GLP-1 veiqaravi e gadrevi kina e dua na iwalewale ni veisautaki ni kemikali e vuqa me tarova ena dua ga na gauna na veibiu ni enzymatic ., vakamalua na vakasavasavataki ni renal, kei na maroroi ni veivakadeitaki ni veivakadeitaki ($EC_{50}$).
[Native GLP-1 (7-36)] : H2N-His7-Ala8-Glu9-Gly10-Thr11-Phe12-Thr13-Ser14-Asp15-Val16...-Lys26...-Lys34-Gly37-OH
|
(DPP-IV Cleavage Point)
[Engineered Analog] : H2N-His7-[Aib8]-Glu9-Gly10-Thr11-Phe12-Thr13-Ser14-Asp15-Val16...-[Lys26(Spacer-FattyAcid)]...-[Arg34]-Gly37-NH2
| |
(Protease Resistant) (Albumin Binding Handle)
1. Vakadeitaki ni Enzymatic: Veisaqasaqa ni DPP-IV
Substituting the native $\text{Ala}^8$ residue with $\alpha$-aminoisobutyric acid ($\itukutuku{Aib}^8$) or $D\text{-Ala}^ 8$ vakacuruma na veivakataotaki steric wavolita na $N$-vakaoti gauna ni veivakacacani ni veivakacacani ka sega ni vakaleqa na docking ni alpha-helical ki na GLP-1 na vanua ni veivakabulabulataki ni veivakabulabulataki.
Na ivakarau ni vakacacani tudei ($k_{pusi}/K_m$) me baleta na DPP-IV na veibiu ni enzymatic e vakalailaitaki me vaka na imatai ni ota ni Michaelis-Menten:
$$v = \frac{V_{max} [S]}{K_m \left(1 + \frac{[Au]}{K_i}\dina) + [S]}$$
Where substitution with $\text{Aib}^ 8 $ vakalevutaka na kaukauwa ni veivakabulabulataki ni vanua ($\Delta G^\ddagger$), vakalailaitaka na iwiliwili ni veibiu ($k_{obs} < 10^{-6}\itukutuku{ s}^{-1}$).
2. Kemisitiri ni wai: C16 vs. C18 Na droini ni diacid
Na veivakaduavatataki ni veivakaduavatataki ni veivakaduavatataki ni asidi ni uro e vakatorocaketaka na veivakaduavatataki ki na Albumin ni Serum ni Tamata (HSA, $K_d \sim 10-50\text{ }\mu\text{M}$), vakalailaitaka na veivakasavasavataki ni yatevuso kei na taqomaka na sui ni peptide mai na endopeptidases sega ni vakatabakidua.
E vakaraitaka na vakadidike e tabaki ena […] Vakasamataka tale na peptides ena lipidation veimama-bula vakabalavutaki Kinetics, veisau mai na dua na C16 palmitoyl mono-asidi (Na droini ni liraglutide, $t_{1/2} \sim 13\text{ h}$) to a C18 octadecanedioic acid diacid via a flexible $\gamma\text{-Glu-OEG}_2$ na veimama ($\gamma\text{-L-kulutamili-(\beta-alanila-2,2′-(etilenidiokisi)bisi(etilemina))}$, Na droini ni semaglutide) extends human plasma half-life to $\sim 165\text{ aua}$.
Lys26 Side Chain ($\epsilon$-amine)
|
(NH-CO-CH2)
|
[$\gamma$-Glu Spacer]
|
[OEG Linker 1: 8-amino-3,6-dioxaoctanoic acid]
|
[OEG Linker 2: 8-amino-3,6-dioxaoctanoic acid]
|
[Octadecanedioic Acid: HOOC-(CH2)16-CO-]
3. Kemisitiri ni PEGylation ni vanua-vakatabakidua
Me baleta na sega ni covalent se vakabalavutaki na ivakarau ni vakasoqoni, monodispersa o multidispersa Poly(etileni kalaikoli) (PEG, 20-40 kDa) e semati ena iqaqalo ni bula-vakatautauvatataki ni vanua:
- Veisemati ni Tioli-Maleimidi: Reaction of an engineered $Cys$ residue with Maleimide-PEG at $\text{pH } 6.5 – 7.2$.
- Veisemati ni Oxime: Reaction of an aminooxy-functionalized PEG with an $N$-terminal aldehyde or keto-amino acid at $\text{pH } 4.5 – 5.5$.
Me vaka e volai ena . Na vuli ni kemisitiri ni ACS ena PEGylation ni vanua-vakatabakidua, Na PEGylation e vakarabailevutaka vakalevu na radius ni wai ($R_h$), vakarautaki ena Lawa ni Vakatautauvatataki ni Polimeri:
$$R_h = K_{PEG} \cdot (M_w)^a$$
Where $M_w$ is the PEG molecular weight and $a \approx 0.55-0.60$ ena veivakabulabulataki wai. Ni tarova vinaka na PEGylation na kena vakasavasavataki na glomerules, e rawa ni vakamalumalumutaka na kaukauwa ni veivakabulabulataki ni ciqomi ena vuku ni veitaqomaki steric, gadrevi kina na balavu ni linker vakavinakataki.
4. Vakadidike & Liga ni vakatakilakilataki ni vakadidike
Na vuli vakadewa taumada e gadrevi kina na ADME vakailavo ., Veisoliyaki ni yago, kei na ivakatakilakila ni sela-vesuki. Na kena vakacurumi na ilawalawa ni dauvolaitukutuku e dodonu me vakarautaki vakadodonu me kakua ni vakataotaka na veiwekani ni GLP-1R .:
- Tagi ni lumi: FITC o Cianina5.5. (Cy5.5) vakaveiwekanitaki ena kena vakayagataki na Lysine digitaki se Thiol-alkylation.
- Vakatakilakila ni Isotopi: Unifomu $^{13}\itukutuku{C}/^{15}\itukutuku{N}$ tudei na isotope-vakatakilakilataki na amino asidi e vakacurumi ki na isema ni hydrophobic ni uto me baleta na LC-MS / MS taucoko (Na ivakarau ni MRM/PRM) ena veisele ni plasma ni bera na valenibula.
Na ituvatuva ni ASCII 1: Veitaqomaki ni Orthogonal & Veisemati ni Yasana-Seini
To achieve site-specific acylation at $\text{Lys}^{26}$ while leaving $\text{Lys}^{34}$ (or $\alpha\text{-NH}_2$) sega ni saumi, e dua na ituvatuva ni veitaqomaki vakadodonu e dodonu me vakayacori:
Fmoc-Lys(Mtt)-OH or Fmoc-Lys(Alloc)-OH at Position 26
|
[Assembly of Core Peptide Chain on Resin via SPPS]
|
Selective De-protection of Mtt (1% TFA/DCM) or Alloc (Pd(PPh3)4/PhSiH3)
|
Solid-Phase Coupling: Fmoc-OEG-OH -> Fmoc-OEG-OH -> Fmoc-Glu-OtBu -> Mono-tert-butyl octadecanedioate
|
Global Deprotection & Resin Cleavage (TFA / TIS / H2O / EDT = 92.5 : 2.5 : 2.5 : 2.5)
Me baleta na timi vakatovotovotaka na veitarataravi ni veisau vereverea, vakayagataka e dua na tauyavutaki ituvatuva ni veivakatorocaketaki ni peptide vakaitaukei kei na rawaka ni veitaqomaki orthogonal vakatabui e vakadeitaka na savasava taumada ni crude cecere ni bera na ivakarau ni sobu-cake.
Ivakatagedegede 2 — Na veivakabulabulataki ni iwali-Fase & Idinia ni Veisau
Matrix ni vakatulewa ni leqa: Veivakaduiduitaki & Lewa vakasivia
Ena gauna ni vakalevutaki ni veivakaduiduitaki ni lipophilic (t.s., C18 diacids with $\gamma\text{-Glu-OEG}_2$ veimama), sega ni vinaka duadua na isau ni paramita vakavuna na itukutuku ni dukadukali vakatabakidua:
BIOCONJUGATION TROUBLESHOOTING FLOWCHART
|
+--------------------------------+--------------------------------+
| |
v v
[Symptom: Over-Acylation Impurity] [Symptom: Racemization at Chiral Linker]
(Nα,Nε-bis-acylated product > 1.5%) (D-Glu / D-Lys diastereomer species > 0.5%)
| |
+---> Root Cause: pH > 8.8 (N-terminal +---> Root Cause: Excess base / High Temp
| α-amine becomes unprotonated) | during activated ester coupling
| |
+---> Action: Implement automated +---> Action: Switch from HATU to Oxyma Pure/DIC;
pH-stat titration at pH 8.2-8.5 maintain reaction temperature at 18°C–20°C
| Mode ni sega ni rawata / Na dukadukali | Vuna | Sikinala ni vakadidike | Na iwalewale ni kena vakalailaitaki na iwalewale |
|---|---|---|---|
| $N^\alpha,N^\epsilon$-Bis-Acylation | Reaction $\text{pH} > 8.8$ se stoic vakailesilesi vakasivia. ($>1.5\itukutuku{ tautauvata.}$) | UHPLC cecere co-eluting ni oti na cecere levu ($+M_{uro}$ MW veisau ena MS) | Tighten $\text{pH}$ lewa ki na $8.2-8.5$; vakaiyalayala na kaukauwa. to $1.05-1.15\text{ tautauvata.}$; vakayagataka na pH-stat vakataki koya |
| Na veivakaduiduitaki ni veivakaduiduitaki ($D\text{-Glu}$) | Vakabalavutaki na gauna ni veisau kei na yavu kaukauwa (t.s., DIPEA) ena $ .>25^\circ\text{C}$ | Chiral LC-MS or Marfey’s method showing $D\text{-asidi amino} > 0.2%$ | Vakaisosomitaka na DIPEA kei na $N$-metilimorfolini; lower coupling temp to $18-20^\circ\text{C}$; taura Oxyma savasava / DIC |
| Lipid Ester Hidrolisis / Veisau | Sa rui cecere na ivakarau ni buffer ni wai ($>40%\itukutuku{ H}_2\text{O}$) vakavuna na wai ni ester | MS cecere veiganiti kei na diacid vakalivaliva | Optimize solvent ratio to $\text{DMF/Wai } 80:20\itukutuku{ v/v}$ or $\text{NMP/DMSO}$; tarova na cakacaka ni wai |
Ni veisau lailai-vakatautauvata e rawa ni vakau ena-resin ., Na buli iyaya lelevu e dau vakarota e dua na iwalewale ni hybrid: vakasoqoni vata na sui ni peptide laini ena resin, tarava mai na iwali ni oti na veibiu-iwasewase ni veivakaduavatataki ni lipid sau levu se PEG polymers me vakalailaitaka na benu ni iyaya kaukauwa.
+-----------------------------------------------------------------------------------+
| SOLUTION-PHASE BIOCONJUGATION PARAMETERS |
+--------------------------+--------------------------------------------------------+
| Parameter | Optimal Process Window |
+--------------------------+--------------------------------------------------------+
| Peptide Concentration | 5.0 - 15.0 mM |
| Acylating Agent Stoich. | 1.05 - 1.25 equiv. relative to target Lys |
| Solvent System | DMF / Water (70:30 v/v) or NMP / DMSO mixtures |
| Reaction pH | 8.2 - 8.5 (controlled via N-methylmorpholine or TEA) |
| Reaction Temperature | 18°C - 22°C |
| Coupling Reagents | PyBOP / Oxyma Pure or HATU / HOAt |
+--------------------------+--------------------------------------------------------+
Veidigidigi ni kemikali & $pK_a$ Lewa
Selective acylation of the $\epsilon\text{-amino}$ group of $\text{Lys}^{26}$ ($pK_a \approx 10.5$) over the $N$-terminal $\alpha\text{-amino}$ ilawalawa ($pK_a \approx 8.0$) e gadrevi kina na maroroi ni pH ni buffer dodonu. Operating within a narrow window of $\text{pH } 8.2 – 8.5$ maintains the $\alpha\text{-amina}$ ena dua na ituvaki vakalevu cake ($\itukutuku{-NH}_3^+$), while allowing sufficient unprotonated nucleophilic $\epsilon\text{-amina}$ ($\itukutuku{-NH}_2$) me saumi vata kei na NHS-esters se tetrafluorophenyl (TFP) esita.
Na ikarua ni ota ni iwiliwili ni isau tudei ($k_{obs}$) me baleta na veivakaduiduitaki ni bula digitaki e lewai mai vei:
$$\frac{d[\itukutuku{Veisotari}]}{dt} = k_0 \cdot \left(\frac{1}{1 + 10^{(pK_a – \text{pH})}}\dina) [\itukutuku{Pepitaiti}] [\itukutuku{Vakailesilesi}]$$
Cici na veisautaki ni bula ena loma ni dua na suite vakatabakidua ni veivakaduiduitaki kei na veisau vakaiyaragitaki ena pH-stat vakataki koya na vakasama ni ivoli e vakaotia na ivoli ena yasa ni sivia-acylation ($N\alpha,N\epsilon\text{-bis-asilati}$ manumanu).
Ivakatagedegede 3 — Vakarautaki-Cake na Iunite ni Cakacaka: SPPS ki na SPPS-LPPS veiwaki ni veivakaduiduitaki
Vakarautaka na GLP-1 buli mai na levu ni idabedabe ni vale ni vakadidike (0.1-1,0 g) ki na kilokaramu pailate ilawalawa e vakacuruma na vakaiyalayala ni idinia ni katakata kei na vakayago.
[LAB SCALE: Pure SPPS] [PILOT/COMMERCIAL SCALE: Hybrid SPPS-LPPS]
0.1 - 100 g Batch Capacity 1.0 kg - 100 kg Batch Capacity
- High DMF/NMP consumption (>1000 L/kg) - Slashes solvent consumption by 60%
- Crude purity drops on long sequences - Fragment purity >95% prior to condensation
- Resin swelling & pressure drop limits - Controlled solution-phase thermodynamics
1. Fase-Malumalumu vs. Na vakawaicalataki ni tikitiki ni wai
Na SPPS ni laini ni 30-40 mer GLP-1 e sotava na kena kumuni vakalevu na dukadukali ni truncation ($n-1., n-2$) Ena vuku ni kena vakasoqoni vata na steric ena idavodavo ni resin. Me vaka e vakamacalataki ena . Na vakadidike ni vanua ni kila ni Bachem ena SPPS ni bisinisi, lutu sobu na iwiliwili taucoko ni vua ni waiwai $20%$ ena ivakarau kevaka e cakacakataki vakalaini taucoko.
Me rawa ni vakadrukai oqo ., parokaramu ni vakadewa ni gauna oqo e vakayagataka SPPS-LPPS veiwaki ni veitiki ni vakasaqa, me vaka e vakaraitaka na . PDA ivola ena veivakaduiduitaki ni tikitiki ni SPPS-LPPS.
Na tikitiki ni peptide taqomaki lekaleka (t.s., Tikina A: vo ni 7–14; Tikina B: vo 15–26; Tikina C: vo ni 27–37) era sa buli vakatikitiki ena 2-kolorotritil koloraidi resin, cleaved ena ruku ni ituvaki malumu ni asidi ($0.5-1.0%\itukutuku{ TFA}$ ena DCM) me maroroi na ilawalawa ni veitaqomaki ena yasana, kei na kena e muri cokovata ena iwasewase ni iwali:
Fragment A (7-14)-OH + H-Fragment B (15-26)-OtBu
| (Coupling: DIC / Oxyma Pure, DMF/DCM, 20°C)
v
Protected Intermediate AB (7-26)-OtBu
| (Deprotection)
v
H-Intermediate AB (7-26)-OH + H-Fragment C (27-37)-NH2
| (Coupling: PyBOP / HOAt)
v
Full-Length Protected GLP-1 Analog
| (Global Deprotection: TFA Cocktail)
v
Crude GLP-1 Conjugate
Na ivakatagedegede ni vakatovotovo: Ena veivakatovolei ni pailate (1.0–5.0 kg ilawalawa cici), adopting oqo 3-tikina SPPS-LPPS vakasavasavataki ni ivakarau tudei rawata na iwali-wasewase ni tiki ni veimaliwai e rawata $ .> 85%$ na savasava ni tikitiki taqomaki $ .> 92%$ ni bera na iotioti ni vakacegu. Kena ikuri, elevating RP-HPLC column temperatures to $50^\circ\text{C} – 55^\circ\text{C}$ ena gauna ni vakasavasavataki ni vakavakarau ni C4 e walia na veivakasaurarataki ni lipophilic, vakavinakataka na vua ni vakabulabulataki ena . $18-22%$ vakatauvatani ki na cici ni katakata ni ambient.
2. Vakarautaki-Cake & Kolomu sega ni laini
Na vakasavasavataki ni lipidated se PEGylated GLP-1 peptides e vakararavi ena HPLC ni Veisau-Iwasewase (RP-HPLC) vakayagataka na C4 se C18 silica vakatikitiki ($100-300\itukutuku{ \AA}$ Levu ni qara, $10\itukutuku{ }\mu\text{m}$ levu ni tikitiki).
Ena gauna ni vakalevutaki, cecere ni idavodavo ni duru ($L$) kei na totolo ni laini ($u$) e dodonu me maroroi tudei ni vakarautaki na diamita ni duru ($D$) me maroroi na vakatulewa ni roka ($R_s$):
$$\frac{V_1.}{V_2.} = \left(\frac{D_1}{D_2.}\dina)^2$$
$$R_s = \frac{\sqrt{N}}{4} \imawi(\frac{\alifa – 1}{\alfa}\dina) \imawi(\frac{k’}{1 + k’}\dina)$$
CHROMATOGRAPHIC RESOLUTION DYNAMICS
Analytical (4.6 mm ID) Preparative (50 mm ID) Industrial (300-600 mm ID)
[Peak A][Peak B] --> [ Peak A ][ Peak B ] --> [ Peak A ][ Peak B ]
(Sharp separation) (Slight peak broadening) (Mass loading non-linearity)
Na sinucodo lipid ni wai e vakalevutaka na gauna ni maroroi ($k’$), e gadrevi kina na ivakarau ni cakacaka ni duru cecere ($45^\circ\text{C} – 60^\circ\text{C}$) kei na veisautaki ni veika bula (Isopropanol/Acetonitrile in $0.1%\text{ TFA}$ or $20\text{ mM } \itukutuku{NH}_4\text{OAc}$) me tarova na vakadukadukalitaki ni duru kei na veivakacacani.
Ivakatagedegede 4 — Na ivakatakilakila ni vakadidike cecere & Na ivakatagedegede ni sereki
Na rawaka ni vakadewa e gadrevi kina na veivakadeitaki kaukauwa ni vakadidike me vakadeitaka na ivakatakilakila ni kemikali, savasava, kei na galala mai na veika e buli mai na immunogenic ..
ESI-HRMS MASS SPECTRUM (MOL Changes CoA Validation)
100| [M+3H]3+ m/z = 1371.6842
| |
50| [M+4H]4+ | [M+2H]2+
| m/z = 1029.0151 | m/z = 2057.0238
0+-------------------------------------------------> m/z
Na iwalewale ni vakadidike
- Ultra-cecere na cakacaka ni wai (UHPLC): Method optimized for resolving $D\text{-Glu}$, $D\text{-Ala}$, and $\beta\text{-Asp}$ tuvanaki tale ni isomer.
- Na ioni ni livaliva cecere-vakatulewa levu (ESI-VAKAVUVULI): Vakatulewa dodonu ni levu ena loma ni $ .< 5\itukutuku{ ppm}$ cala ni vanua me vakadeitaka na bibi ni molecule ni monoisotopic dodonu.
- Veitarataravi ni MS/MS: Veisemati e vakavuna na veicoqacoqa (CID) se na Veisau ni Veisau ni Ilektroni (ETD) me vakadeitaka na itutu ni veivakadeitaki ni lipid/PEG ni vanua.
Sitivikiti ni vakadidike raraba (CoA) Na ivakamacala
Na teveli e ra e vakaraitaka na ivakatagedegede ni sereki ni kalasi ni lawa e gadrevi me baleta na vakadewataki ni GLP-1 peptide conjugates .:
| itovo vinaka | iwalewale ni veivakatovolei ni vakadidike | Na ivakatagedegede ni ciqomi | Na vuna vakasaenisi |
|---|---|---|---|
| ivakatakilakila ni kemikali | ESI-VAKAVUVULI / Maldi-Tof MS | Veisotari vakarautaki MW ($\pm 0.05\text{ Kei}$) | Vakadeitaka na isema ni amino asidi taumada kei na veisau |
| Savasava ni kemikali | RP-HPLC / UHPLC ($214\itukutuku{ nm} / 280\itukutuku{ nm}$) | $\ge 98.0%$ (Vanua %) | Vakalailaitaka na dukadukali ni peptide vakalailaitaki kei na oxidized |
| Dua ga na dukadukali | RP-HPLC / LC-MS | $\na 0.5%$ | E vakaiyalayala sara na dua ga na $n-1$ se na veimataqali |
| Na veika dukadukali taucoko | RP-HPLC | $\na 2.0%$ | E salavata kei na ICH Q3A na ivakatagedegede ni lawatu |
| Savasava vakayago | GC-MS / Na iwalewale nei Marfey | $\le 0.2\text{ D-amino asidi}%$ | Tarova na yali ni veivakabulabulataki ni veivakabulabulataki kei na veivakabulabulataki |
| TFA sa vo | Na roka ni ioni (IC) | $\le 0.5%\text{ w/w}$ (se Veisau ki na Acetate/HCl .) | Na TFA sivia e vakavuna na veivakacacani ena veivakatovolei yavutaki ena sela |
| Na veika e vo | Na roka ni kasi (GC-HS) | DMF $< 880\itukutuku{ ppm}$, NMP $< 530\itukutuku{ ppm}$ | Sotava na kalasi ni ICH Q3C 2 iyalayala ni taqomaki ni wai |
| Lewe ni Endotoxin | LAL Vakatovolei ni Kromojini | $< 0.01\itukutuku{ EU/mg}$ | Critical for $in\text{ bula}$ vuli ni manumanu ni bera na valenibula |
| Na vakaluveni ni manumanu lalai | Vakadodonu na veivakasavasavataki ni membrane | Lako (Sega ni tubu ena . 14 siga) | Vakadeitaki ena Kalasi 1.1. 100 cakacaka ni rumu savasava |
Vakadeitaka e dua na matata ., taucoko na kena vakamuri na CoA mai na dua na itokani e vakarautaka ivakatakilakila cecere ni HPLC/MS CoA vakaotia na veivakataotaki ni veivakadeitaki ni bera na vakau ni IND.
Ivakatagedegede 5 — Na digidigi ni buli iyaya e tubu tiko mai .: GMP-Vakarau 3D tabaki & Na ivakarau ni veisoliyaki vou
Ni sa vakayagataki na wai makawa (veisele ena ruku ni kuli) lewa na veiqaravi ni GLP-1 ena gauna oqo, na parokaramu ni vakadewa era sa vakayagataka tiko na ituvatuva ni buli iyaya torocake —vakabibi . GMP-Vakarau 3D tabaki kei Vakavotukanataki ni wai lalai—me dolava na sala ni veiqaravi ni gusu kei na depot e veiganiti kei ira na tauvimate.
GMP-READY 3D PRINTING & FORMULATION PATHWAYS
|
+-------------------------+-------------------------+
| |
v v
[Semi-Solid Extrusion (SSE)] [Subcutaneous Implants]
- Multi-layer gastro-resistant oral tablets - Biodegradable PLGA/PCL matrix
- pH-responsive Eudragit L100-55 coatings - Zero-order sustained release (1-3 months)
- Protects peptide from stomach pepsin/acid - Eliminates peak-to-trough plasma spikes
1. Vakavotukanataki Semi-Malumalumu (SSE) 3D Tabaki me baleta na veisoliyaki ni gusu
Na veiqaravi ni gusu ni GLP-1 peptides e vakaleqai sara vakalevu ena vakacacani ni asidi ni kete ($\itukutuku{pH } 1.5 – 2.0$) kei na vakasavasavataki ni enzymatic ena pepsin kei na trypsin ena kete lailai.
Me vaka e vakaraitaki ena . Vakadidike ni veika bula ena 3D-tabaki Peptide wainimate ni veisoliyaki, Vakavotukanataki Semi-Malumalumu (SSE) 3D tabaki e rawa kina na buli ni fomu ni kaukauwa ni gusu kei na geometries ni uto-shell vereverea:
- Uto: Na GLP-1 vakalivaliva e buli vata kei na veivakatorocaketaki ni veivakabulabulataki (t.s., Sodium Caprate / IVAQA).
- Qana: 3D-tabaki rede ni polimeri enteric (Eudragiti L100 / HPMC-ME VAKA) ni se sega ni vakawaicalataki rawa ena pH ni kete, vakawabokotaki totolo ga ni sa yaco ki na duodenum . ($\itukutuku{pH } > 6.0$).
$$\itukutuku{Na iwiliwili ni kena vakawabokotaki } \imawi(\frac{dM}{dt}\dina) = \frac{A \cdot D \cdot (C_s – C_b)}{h}$$
3D paramita ni tabaivola (nozzle diameter $200-400\text{ }\mu\text{m}$, extrusion pressure $2.0-4.5\text{ iqaqi}$, temperature $25^\circ\text{C} – 35^\circ\text{C}$) vakatara na kena vakarautaki vakadodonu na geometry ni vanua ka sega na vakacacani ni katakata ni peptide API.
2. Na vakasavasavataki ni yago-shell me baleta na vanua ni vakaruru ena ruku ni kuli
Me sosomitaka na veisele vakawasoma ena ruku ni kuli ., tomani tikoga na ivakarau ni tabaivola ni 3D microfluidic bulia na Poly(lactic-ko-laikoliki asidi) (PLGA) o Polikaprolaktoni (PCL) veivakabulabulataki lalai.
Ena kena lewai na kinetics ni vakacacani ni polymer ($\itukutuku{NA:GA}$ iwiliwili $50:50 \gasau imatau 75:25$), na itukutuku ni sereki e rawa ni idinia me vakaraitaka na veisoliyaki ni zero-ota ena 30 me 90 siga, maroroya na ivakarau ni plasma ni veiqaravi tudei ($C_{ss}$) ena loma ni katubaleka ni veiqaravi ($C_{miniti} < C_{ss} < C_{max}$).
Vakarau ni Veivakalawataki & ICH ivakarau ni kena muri
Na parokaramu ni vakadewa veisau mai na kunei ni gauna ni bera ki na Wasewase 1. 1 na veivakatovolei ni valenibula e dodonu me salavata kei na cakacaka ni buli iyaya kei na Matabose ni Veimatanitu me baleta na Veivakaduavatataki (Au) idusidusi:
[ICH Q3A(R2)] : Control of Impurities in New Drug Substances (Threshold: > 0.05% ID, > 0.10% Qualification)
[ICH Q3B(R2)] : Control of Impurities in Finished Drug Products
[ICH Q3C(R8)] : Residual Solvent Control (DMF, NMP, DCM, Acetonitrile limits)
[ICH M7] : Assessment and Control of DNA Reactive (Mutagenic) Impurities
Na cakacakataki ni sterile ena vanua ni rumu savasava
Baleta na vakasucumi ni oti na kena buli (autoclave se radiación gamma) vakavuna na vakacacani ni kemikali ni lipid kei na PEG na yasa ni sinucodo, iotioti ni peptide vakatikitikitaki kei na vakamamacataki e dodonu me yaco ena loma ni dua na vakadeitaki Kalasi 100 rumu savasava sara. Maroroya na ISO 5 / Na ituvaki ni drodro ni kalasi A laminar e tarova na pyrogen kei na vakadukadukalitaki ni manumanu lalai ena gauna ni vakasinaiti ni pauta levu.
Rawa ni Vakadewa & Mape ni Sala ni Veivakayacori
Me dusimaki ira na saenitisi ni biopharma ena digidigi taumada ni veitarataravi me vakayacori kina na ivakarau-cake ., na matrix ni vakatulewa e ra e vakasoqona vata na veisau bibi ni veisau-offs:
| Digidigi ni Veisau | Yaga Taumada ($in\text{ }bula$) | Vakalevutaka-Cake na Boto | iWalewale ni Veivakalailaitaki |
|---|---|---|---|
| Aib8 Veisosomitaki | Veisaqasaqa ni DPP-IV | Na cakacaka ni veiwekani lailai ena vuku ni $N$-vakataotaki ni steric ni icavacava | Vakayagataka na HATU/HOAt se vakaruataki na veiwekani ena ivakarau ni katakata cecere ($50^\circ\text{C}$) |
| C18 Na waiwai ni Diasidi | Vakabalavutaki na veimama ni bula ($>160\itukutuku{ h}$), HSA vesuki | Na malumalumu ni vakawaicalataki, jela ni resina, vereverea ni HPLC vakasavasavataki | Na veivakaduiduitaki ni bula ni iwali ni oti na veibiu; C4 RP-HPLC at $50^\circ\text{C}$ |
| PEGila (20-40 kDa) | Sega na vakagalalataki ni renal | Veisoliyaki vakalevu, tubu ni kaukauwa, vakalailaitaka na cakacaka ni bula | Veisemati ni thiol-maleimide ni vanua; Digidigi kaukauwa ni PEG duabau |
| 3D Tabaki Gusu Solid | Na kena muri na tauvimate cecere | Na vakasama ni katakata ena gauna ni vakasaqa, lailai na kena vakayagataki ena gusu | Tabaki ni SSE ena katakata lailai; co-vakarautaki kei na veivakatorocaketaki ni veivakacurumi |
Veitokani me baleta na Rawaka ni Vakadewa
Na vakadewataki ni veidigitaki ni incretin vereverea e gadrevi kina e dua na cakacaka cokovata ka vakacuruma na kemisitiri, vakadidike, kei na kena muri na lawa. MOL Changes (https://molchanges.com/) vakarautaka e dua na R raraba .&D ituvatuva vakarautaki vakatabakidua me baleta na veivakavoui ni biopharma:
- Suite ni Veisau Rabailevu: Sa cava 300 veisautaki ni ilawalawa ni cakacaka, okati kina na diacidi ni lipid vakaitaukei, Veisemati ni PEG, amino asidi vakatakilakilataki vakaisotopi, kei na ivakatakilakila ni cina.
- Kalasi 100 Na veiqaravi ni rumu savasava: Na vanua ni buli iyaya sega ni vakaluveni ni matanitu-ni-na-cakacaka e vakadeitaka na endotoxin lailai sara ($< 0.01\itukutuku{ EU/mg}$) kei na vakaluveni ni manumanu lalai.
- Vakatautauvatataki: Milikaramu vakadidike ni vakadidike ki na multikaramu / kilokaramu pailate ni veivakaduavatataki kei na vakadeitaki ni ilawalawa-ki-ilawalawa.
- Vakadeitaka na ivakarau ni CoA kaukauwa: HPLC taucoko, ESI-VAKAVUVULI, kei na ivakarau ni savasava ni chiral e salavata mai kei na veika kece e vakadewataki.
Veisureti ni Veivakatovolei Vakatekinikali: O sa vakavinakataka tiko beka e dua na GLP-1 se incretin co-agonist veitarataravi me baleta na vakadewataki ni veiqaravi vakavuniwai? Veitaratara kei na veisau ni MOL me kerei kina e dua na railesuva na rawa ni veivakabulabulataki ka vakalewa na nomu veitarataravi ni veitarataravi ., vakawaicalataki, kei na paramita ni vakalevutaki kei na noda timi ni idinia ni kemikali qase.
Veidusimaki
- Knudsen, L. B., & Lau, J. (2019). Na kena kunei kei na kena vakatorocaketaki na Liraglutide kei na Semaglutide .. Na iyalayala ni veisele, 10, 155. DOI: 10.3389/2019.00155 | PMID: 31024456 | Railesuva na veimama ni bula vakabalavutaki
- Prada Brichtova, E., kei na so tale. (2024). Na kena revurevu ni lipidation ena ituvatuva, Vakalailaitaki, kei na kena vakasoqoni vata na Peptide vaka na glucagon 1. Kemisitiri ni ACS, 35(4), 484-495. DOI: 10.1021/acs.kemi ni bula.4c00012 | PMC: PMC10959496
- Valenivolavola ni kila ka ni Bachem. (2024). GLP-1 Gadrevi: Na cava na kena ibalebale vei ira na dau buli Peptide ni bisinisi. Pepa vulavula ni bisinisi ni Bachem
- iSoqosoqo ni wainimate gaga (PDA). (2025). Na veivakavoui ni veivakacacani e bulia na vanua ni GLP-1: SPPS-ki-LPPS veiwaki ni veivakaduiduitaki. Tukutuku ni ivola ni PDA. PDA tabaki ni mataveilawa
- Zhang, Y., kei na so tale. (2025). Tuvatuva ni GLP-1 Veisoliyaki: Na rai ni ituvatuva kei na iwalewale ni kena buli na tabaki ni 3D me baleta na veiqaravi vakavinakataki. Ripote vakasaenisi ni veika bula, 10, 397. DOI: 10.1038/s41598-025-00397-41.
- Matabose ni Veimatanitu me baleta na Veivakaduavatataki (Au). (2023). Au Q3A(R2.): Na dukadukali ena veika vou ni wainimate gaga & Au Q3C(R8.): Veivakarautaki ni Veiliutaki Lekaleka me baleta na idusidusi ni veivakabulabulataki ni veivakabulabulataki. Tabacakacaka ni wainimate mai Iurope (EMA) / Na idusidusi ni veivakaduavatataki ni FDA ni Amerika.
